Drug interactions
Armodafinil + Pemigatinib
Severity: Major
Armodafinil and Pemigatinib: major interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Armodafinil may decrease pemigatinib concentrations through CYP3A4 induction. Reduced exposure could lessen anticancer efficacy. Labeling advises avoiding strong and moderate CYP3A4 inducers.
What this interaction means in plain words
Armodafinil and Pemigatinib can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for.
Armodafinil belongs to Central Nervous System; Pemigatinib belongs to Oncology.
Why it happens
CYP3A4 induction by armodafinil increases the metabolism of pemigatinib, a CYP3A4 substrate.
What to do
Avoid the combination and use a non-inducing alternative to armodafinil. If it cannot be avoided, monitor for loss of tumor response.
What to ask your pharmacist
- Does the benefit of taking both outweigh the risk in my case?
- Do I need any blood test, ECG or other check while on both?
- What early warning signs should I watch for, and what should I do if they appear?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Armodafinil and Pemigatinib, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 14 days on the web. No card needed.
Other interactions of Armodafinil
Other interactions of Pemigatinib
Frequently asked questions
Can I take Armodafinil with Pemigatinib?
MediHelp rates the interaction as major. Armodafinil and Pemigatinib can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for. Armodafinil may decrease pemigatinib concentrations through CYP3A4 induction. Reduced exposure could lessen anticancer efficacy. Labeling advises avoiding strong and moderate CYP3A4 inducers.
How serious is the interaction between Armodafinil and Pemigatinib?
MediHelp rates it major, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Avoid the combination and use a non-inducing alternative to armodafinil. If it cannot be avoided, monitor for loss of tumor response.
What other medicines interact with Armodafinil?
MediHelp also lists interactions of Armodafinil with, for example, Avapritinib, Cyclosporine, Elacestrant. The full list is on the Armodafinil page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
